Voyager Therapeutics, Inc. (VYGR)
VYGR Stock Price Chart
Explore Voyager Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze VYGR price movements and trends.
VYGR Company Profile
Discover essential business fundamentals and corporate details for Voyager Therapeutics, Inc. (VYGR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Nov 2015
Employees
172.00
CEO
Alfred W. Sandrock Jr.,
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
VYGR Financial Timeline
Browse a chronological timeline of Voyager Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 9 Mar 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.50.
Earnings released on 6 Aug 2025
EPS came in at -$0.57 falling short of the estimated -$0.48 by -18.75%, while revenue for the quarter reached $5.20M , missing expectations by -33.83%.
Earnings released on 6 May 2025
EPS came in at -$0.53 falling short of the estimated -$0.35 by -51.43%, while revenue for the quarter reached $6.47M , missing expectations by -53.45%.
Earnings released on 11 Mar 2025
EPS came in at -$0.59 falling short of the estimated -$0.35 by -68.57%, while revenue for the quarter reached $6.28M , missing expectations by -51.51%.
Earnings released on 12 Nov 2024
EPS came in at -$0.16 surpassing the estimated -$0.45 by +64.44%, while revenue for the quarter reached $24.63M , beating expectations by +59.35%.
Earnings released on 6 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$0.38 by +52.63%, while revenue for the quarter reached $29.58M , beating expectations by +212.66%.
Earnings released on 13 May 2024
EPS came in at -$0.20 surpassing the estimated -$0.44 by +54.55%, while revenue for the quarter reached $19.52M , beating expectations by +107.40%.
Earnings released on 28 Feb 2024
EPS came in at $1.25 surpassing the estimated -$0.29 by +531.03%, while revenue for the quarter reached $90.06M , beating expectations by +336.55%.
Earnings released on 6 Nov 2023
EPS came in at -$0.59 falling short of the estimated -$0.58 by -1.72%, while revenue for the quarter reached $4.61M , missing expectations by -17.01%.
Earnings released on 3 Aug 2023
EPS came in at -$0.51 surpassing the estimated -$0.59 by +13.56%, while revenue for the quarter reached $4.85M , beating expectations by +174.18%.
Earnings released on 9 May 2023
EPS came in at $2.94 surpassing the estimated $0.77 by +281.82%, while revenue for the quarter reached $150.48M , beating expectations by +146.24%.
Earnings released on 7 Mar 2023
EPS came in at -$0.61 falling short of the estimated -$0.57 by -7.02%, while revenue for the quarter reached -$41.09M , missing expectations by -1.08K%.
Earnings released on 8 Nov 2022
EPS came in at $0.45 surpassing the estimated -$0.32 by +240.63%, while revenue for the quarter reached $41.09M , beating expectations by +336.34%.
Earnings released on 4 Aug 2022
EPS came in at -$0.50 surpassing the estimated -$0.56 by +10.71%, while revenue for the quarter reached $712.00K , missing expectations by -89.87%.
Earnings released on 4 May 2022
EPS came in at -$0.56 falling short of the estimated -$0.14 by -300.00%, while revenue for the quarter reached $658.00K , missing expectations by -94.82%.
Earnings released on 8 Mar 2022
EPS came in at $0.15 surpassing the estimated -$0.32 by +146.87%, while revenue for the quarter reached $28.07M , beating expectations by +553.41%.
Earnings released on 2 Nov 2021
EPS came in at -$0.67 surpassing the estimated -$0.75 by +10.67%, while revenue for the quarter reached $1.48M , missing expectations by -19.46%.
Earnings released on 9 Aug 2021
EPS came in at -$0.80 falling short of the estimated -$0.75 by -6.67%, while revenue for the quarter reached $1.36M , meeting expectations.
Earnings released on 10 May 2021
EPS came in at -$0.58 surpassing the estimated -$0.71 by +18.31%, while revenue for the quarter reached $6.50M , missing expectations by -10.81%.
Earnings released on 25 Feb 2021
EPS came in at -$0.43 surpassing the estimated -$0.52 by +17.31%, while revenue for the quarter reached $6.54M , missing expectations by -18.84%.
Earnings released on 9 Nov 2020
EPS came in at $2.27 surpassing the estimated -$0.19 by +1.29K%, while revenue for the quarter reached $117.84M , missing expectations by -92.03%.
VYGR Stock Performance
Access detailed VYGR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.